SeaBridge Investment Advisors LLC Increases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

SeaBridge Investment Advisors LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 10.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,557 shares of the company’s stock after acquiring an additional 527 shares during the quarter. SeaBridge Investment Advisors LLC’s holdings in Johnson & Johnson were worth $804,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Vinva Investment Management Ltd boosted its holdings in Johnson & Johnson by 6.8% in the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock valued at $17,988,000 after purchasing an additional 7,110 shares in the last quarter. Financial Counselors Inc. grew its position in Johnson & Johnson by 5.3% in the 3rd quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock valued at $29,996,000 after buying an additional 9,309 shares during the last quarter. Meridian Investment Counsel Inc. increased its position in Johnson & Johnson by 19.6% during the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock worth $3,667,000 after purchasing an additional 3,710 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Johnson & Johnson by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock valued at $2,858,543,000 after purchasing an additional 102,502 shares in the last quarter. Finally, Lord Abbett & CO. LLC acquired a new position in Johnson & Johnson during the third quarter worth $69,859,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Morgan Stanley dropped their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Finally, Guggenheim upped their target price on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research report on Monday. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $170.67.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

NYSE JNJ opened at $153.54 on Wednesday. The company has a 50-day moving average price of $147.53 and a two-hundred day moving average price of $156.10. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a market cap of $369.66 billion, a price-to-earnings ratio of 23.09, a price-to-earnings-growth ratio of 2.44 and a beta of 0.52. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $2.29 earnings per share. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.23%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.